A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Carboplatin (KYXATA)

Platinum-based Drug class · 12 generic manufacturers · 45 ANDAs filed at FDA.

First FDA approval2004-10-14
Generic availableYes · 12 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$293,258 in CY2024 Part D spend6K claims · 2K beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Carboplatin used for?

Carboplatin is a Platinum-based Drug medication tracked in Medicare Part D.

Is there a generic for Carboplatin?

Yes. 45 ANDAs filed at FDA, 12 generic manufacturers currently shipping.

How much does my plan pay for Carboplatin?

NADAC pricing data not currently available for this drug.

Is Carboplatin on the FDA shortage list?

Yes. Carboplatin is currently listed as an active FDA shortage.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Platinum-based Drug2 alternatives in D1
01
Cisplatin
Platinum-based Drug
Lowest NADAC
6Generic mfrs
$58,465CY24 Part D spend
Compare →
02
Oxaliplatin
Platinum-based Drug
Lowest NADAC
13Generic mfrs
$1.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.